You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion Biopharma supports the 2020 Primary Immunodeficiency Week

The company stands alongside the global PI community

read more 

EVENTS

World Hemophilia Day: socially distant but still united with patients

Now more than ever, Kedrion is renewing its commitment to those who live with this rare disorder

read more 
  1. EVENTS - 09-11-2015

    Kedrion among the key players of Farmindustria's roadshow in Siena

    The Lucca-based company presented as one of the innovative pharmaceutical companies in Tuscany

    read more 
  2. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 
  3. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 
  4. CORPORATE - 21-09-2015

    Cash Tender Offer for Notes due 24 April 2019

    Kedrion S.p.A. announced Cash Tender Offer for its €300,000,000 4.625 per cent. outstanding Notes due 24 April 2019

    read more 

Pages

For more information please contact: pressoffice@kedrion.com